While research suggests that increasing dietary intake of lignans (nutrients found in whole grains, vegetables, fruits and seeds) may reduce the risk of breast cancer, the findings from studies testing this hypothesis remain inconsistent.
A study published in Cancer Epidemiology, Biomarkers & Prevention examines how women of different backgrounds metabolise lignans.
What these scientists have learned may help explain why associations between diet and breast cancer risk have been difficult to demonstrate consistently.
Lignans are phytoestrogens that are structurally similar to naturally occurring steroid hormones.
A team of researchers led by Susan McCann, PhD, RD, Professor of Oncology in the Department of Cancer Prevention and Control, conducted a dietary intervention study in 137 healthy, postmenopausal Caucasian women and 115 healthy, postmenopausal African-American women in Western New York.
Participants were randomly assigned to either maintain their usual diet or to consume 10 grams per day of ground flaxseed, the richest known source of lignans, for 6 weeks.
Then, after a 2-month period with no dietary interventions, all participants crossed over to the other diet for an additional 6 weeks.
The team, which also included first author Huiru Chang, MS, MA, analysed the urine of participants before and after the flaxseed intervention and compared the excretion of the phytoestrogen enterolactone (ENL) – which has been associated with lower risk of breast cancer, by genotyping 29 genes related to steroid hormone metabolism.
The team identified several individual single-nucleotide polymorphisms or SNPs.
The most common type of genetic variation that was associated with lignan excretion was found particularly among African-American women.
They also observed lower excretion of enterolactone at all time points for African-American women compared to women of European extraction, suggesting that genetic variation may, in part, be involved in the racial differences in ENL excretion.
Based on these results, the team concluded that future dietary interventions to reduce breast cancer may benefit from incorporating information on genetic variation in metabolism.
Most previous genetic studies, they note, have been conducted almost exclusively in populations of European ancestry.
“The fact that we observed lower excretion of enterolactone in women of African ancestry suggests that more enterolactone is remaining in circulation in these women, which may help us to account for some of the differences in disease occurrence observed between African-American and Caucasian women,” explained Dr McCann, senior author on this publication. “Our study adds to the evidence that individual differences in metabolism of diet-related exposures may be important considerations in the development of dietary interventions to reduce disease risk.”
Source: Roswell Park